Jul. 25 at 8:26 AM
$SLS This is how I think a cash-rich tier-one player like
$JNJ extracts maximum value. When you buy an institutional oncology monopoly, you buy total corporate optionality. They would keep the WT1 platform (GPS) for AML to slot perfectly into their hematology footprint alongside Darzalex, locking down a global monopoly on post-remission maintenance. Simultaneously, J&J would hold SLS009 (CDK9i) to serve as the baseline combination booster for their multi-billion-dollar ADC pipeline, successfully bypassing internal tumor shielding. Instead of funding costly trials for 20+ solid tumors themselves, they can easily package those specific rights and out-license them to a rival like
$MRK for massive upfront fees and recurring royalties. By buying
$SLS outright, J&J protects its blockbuster blood cancer franchise, supercharges its internal ADCs, and forces competitors to pay them royalties to fix checkpoint resistance. Just my two cents. 🥂
